BIIB vs. UTHR: Biogen vs. United Therapeutics Stock Comparison

November 11, 2026

How do Biogen (BIIB) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Biogen (BIIB) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Biogen (BIIB) and United Therapeutics (UTHR)
Profile Item	BIIB	UTHR
Name	Biogen Inc.	United Therapeutics Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	36.71 billion USD	23.94 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	September 17, 1991	June 17, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BIIB

UTHR

GSPC

Biogen (BIIB) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Biogen (BIIB) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Biogen (BIIB) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Biogen (BIIB) and United Therapeutics (UTHR)
Metric	BIIB	UTHR
Total Return (1Y)	65.44%	28.77%
Total Return (3Y, Annualized)	4.62%	37.63%
Total Return (5Y, Annualized)	-0.96%	23.78%

Risk Profile

Drawdown History

BIIB

UTHR

GSPC

Biogen (BIIB) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Biogen (BIIB) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Biogen (BIIB) and United Therapeutics (UTHR)
Metric	BIIB	UTHR
Volatility (1Y, Annualized)	34.58%	35.00%
Beta (5Y)	0.08	0.49
Max Drawdown (5Y)	-64.35%	-33.00%
Avg. Volume (3M)	1.05M	694.55K

Risk-Adjusted Performance

Risk-Return Positioning

BIIB and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Biogen (BIIB) and United Therapeutics (UTHR)
Metric	BIIB	UTHR
Sharpe Ratio (1Y)	1.77	0.70
Sortino Ratio (1Y)	2.77	1.29

Profitability

ROE (TTM)

United Therapeutics (UTHR) at 19.13% sits in the top ROE quartile, while Biogen (BIIB) at 1.87% is closer to the peer norm — stronger capital efficiency for UTHR.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max: 109.18%
Q3: 6.23%
BIIB: 1.87%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

United Therapeutics (UTHR) at 38.61% converts revenue to bottom-line profit above its industry’s benchmark range, while Biogen (BIIB) at 3.38% keeps roughly the typical share for its industry.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max: 18.05%
Q3: 4.78%
BIIB: 3.38%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Biogen (BIIB) at 24.12% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max: 83.12%
BIIB: 24.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Biogen (BIIB) and United Therapeutics (UTHR)
Metric	BIIB	UTHR
ROE (TTM)	1.87%	19.13%
ROA (TTM)	4.94%	10.91%
Net Margin (TTM)	3.38%	38.61%
Operating Margin (TTM)	24.12%	28.99%
Gross Margin (TTM)	75.77%	86.34%

Growth

Revenue Growth

Both Biogen (BIIB) at 2.22% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Biogen (BIIB) at -21.38% and United Therapeutics (UTHR) at 13.07% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Biogen (BIIB) and United Therapeutics (UTHR)
Metric	BIIB	UTHR
Revenue Growth (YoY)	2.22%	10.61%
Revenue Growth (3Y CAGR)	-0.94%	18.02%
EPS Growth (YoY)	-21.38%	13.07%
EPS Growth (3Y CAGR)	-25.04%	22.92%

Financial Strength

Current Ratio (MRQ)

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Biogen (BIIB) at 1.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BIIB.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BIIB: 1.95
Min: 0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Biogen (BIIB) carries debt-to-equity ratio of 0.41 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max: 1.42
Q3: 0.65
BIIB: 0.41
Median: 0.15
Q1: 0.02
Min: 0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Biogen (BIIB) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; BIIB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Biogen (BIIB) and United Therapeutics (UTHR)
Metric	BIIB	UTHR
Current Ratio (MRQ)	1.95	4.61
Debt / Equity (MRQ)	0.41	--
Net Debt / EBITDA	1.97	-1.53

Dividends

Dividend Yield (TTM)

Neither Biogen (BIIB) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Biogen (BIIB) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Biogen (BIIB) and United Therapeutics (UTHR)
Metric	BIIB	UTHR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

United Therapeutics (UTHR) at 21.22 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB: 107.51
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Biogen (BIIB) at 3.57 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max: 58.18
Q3: 25.77
Median: 7.30
BIIB: 3.57
Q1: 3.01
Min: 0.01

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Biogen (BIIB) at 1.94 and United Therapeutics (UTHR) at 3.80 are valued close to their industries’ norm against book — neither stands out from peers.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max: 13.53
Q3: 6.54
Median: 3.25
BIIB: 1.94
Q1: 1.69
Min: -5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Biogen (BIIB) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Biogen (BIIB) and United Therapeutics (UTHR)
Metric	BIIB	UTHR
P/E Ratio (TTM)	107.51	21.22
P/S Ratio (TTM)	3.57	7.51
P/B Ratio (MRQ)	1.94	3.80
Free Cash Flow Yield (TTM)	2.20%	1.90%